Veeva Systems Inc. research snapshot
VEEV AI stock analysis currently reads Veeva Systems as a high-quality life sciences software company with durable customer switching costs, a large net cash position, and an expanding AI product cycle across Vault AI, Falcon, Agentic Commercial, and Ostro. Veeva reported fiscal Q1 2027 revenue of $882.9 million, up 16%, net income of $260.9 million, non-GAAP diluted EPS of $2.24, and cash plus short-term investments of about $7.31 billion. The caution is that VEEV still depends on large regulated software budgets, successful Vault CRM migration, and continued AI monetization. At the July 31, 2026 closing reference of $203.78 and 162.44 million shares outstanding, the verified market cap was about $33.10 billion. This VEEV AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$203.78 closing reference on July 31, 2026
Market cap
$33.10 billion equity value
AI score
77 / 100
Rating
High-quality vertical life sciences software platform with strong cash generation, founder-led execution, and a recovering 2026 price trend, but still sensitive to execution and multiple assumptions
Trend status
Above the 5-day, 20-day, 50-day, and 100-day moving averages and testing the 200-day average, with RSI near 62 after a constructive rebound
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Veeva sells industry cloud software, data, AI, and consulting to life sciences companies across commercial, medical, clinical, regulatory, quality, and safety workflows. | High |
| Moat | The moat comes from regulated workflow depth, industry-specific product breadth, customer switching costs, validated data processes, domain trust, and a large installed base across pharma and biotech. | Medium-high |
| Management | Founder and CEO Peter Gassner still directs strategy, product direction, and operations, while investors must watch capital allocation, buybacks, acquisitions, and execution after the Salesforce platform separation. | Medium-high |
| Financial trend | Q1 fiscal 2027 revenue rose 16% to $882.9 million, subscription revenue rose 15% to $730.2 million, GAAP net income rose 14% to $260.9 million, and operating cash flow reached $1.13 billion for the quarter. | High |
| Valuation | At $203.78, VEEV screened near 36.1x trailing EPS, 22.5x fiscal 2027 non-GAAP EPS guidance, 4.6x book value, 20.2x free cash flow per share, and 10.0x sales per share in the audited model. | High |
| Technical trend | The stock is above the 5-day, 20-day, 50-day, and 100-day moving averages and testing the 200-day average near $203.87, with RSI near 62 and a positive directional bias on Barchart. | Medium |
| Risk level | Key risks are Salesforce and IQVIA competition, Vault CRM migration risk, clinical trial and pharma budget cycles, drug pricing and regulatory pressure, AI monetization uncertainty, customer concentration in life sciences, and valuation compression. | Medium-high |
| AI confidence | Descriptive data confidence is high because Veeva provides current official releases and third-party market data is available for cross-checks. | High data confidence |
| Investment certainty | VEEV looks like a high-quality vertical software compounder at a still demanding 2026 multiple, and not a low-risk bargain because the stock prices in successful AI and Vault CRM execution. | Medium |
VEEV AI stock forecast
The VEEV AI stock forecast uses the July 31, 2026 closing reference of $203.78, fiscal 2027 non-GAAP EPS guidance of about $9.05, and a three-year earnings multiple framework. The financial_rigor.py model produced a bearish area near $183, a base area near $274, and a bullish area near $381 before buybacks, dilution, acquisition effects, interest income changes, or further multiple changes. These are scenario ranges, not promises.
$370 to $395
More likely if Veeva keeps revenue growth in the mid-teens, Vault CRM migration strengthens account control, AI products become paid workflow layers, non-GAAP operating margin stays near the mid-40% area, and investors keep paying around 30x forward earnings.
$265 to $285
More likely if EPS grows around 8% to 10% annually, fiscal 2027 revenue lands near the $3.64 billion guidance midpoint, subscription growth stays durable, buybacks offset dilution, and VEEV trades near a 24x earnings multiple.
$175 to $190
More likely if Salesforce Life Sciences Cloud or IQVIA pressure CRM wins, AI features fail to lift spending, clinical trial budgets weaken, margin expansion slows, or software multiples compress toward 18x earnings.
VEEV AI technical analysis
VEEV AI technical analysis is constructive as of the August 2, 2026 data cutoff. StockAnalysis listed a closing price of $203.78 with RSI near 62, while Barchart showed the 5-day average near $201.78, the 20-day average near $193.73, the 50-day average near $178.06, the 100-day average near $173.82, and the 200-day average near $203.87. Price now sits at the 200-day average, so the next few sessions decide whether the rebound continues or stalls.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $203.78 | July 31, 2026 closing reference used for market cap and valuation math. |
| Immediate support | $193 to $202 | The 20-day average near $193.73 and the 5-day average near $201.78 cluster in this zone. |
| Primary support | $178 to $182 | The 50-day simple moving average near $178.06 is the main trend support after the rebound. |
| Trend support | $173 to $176 | The 100-day average near $173.82 marks the deeper recovery support area. |
| Immediate resistance | $204 to $210 | The 200-day average near $203.87 is the immediate test, with the round $210 area overhead. |
| Major resistance | $225 to $245 | StockAnalysis lists a $244.14 analyst price target, so $225 to $245 is the next meaningful supply zone. |
| Moving averages | 20-day near $193.73, 50-day near $178.06, 200-day near $203.87 | Price above the shorter averages supports the recovery, while the 200-day average near $203.87 is the level to reclaim cleanly. |
| Momentum | RSI near 62 with positive directional bias | Barchart shows a 14-day RSI near 62 and a 14-day ADX near 23 with +DI well above -DI, a constructive but not overbought setup. |
| Volume | 20-day average near 1.55 million shares | Breakouts above $210 and $225 should be judged against above-average volume. |
| Volatility | ATR near $8.12 on Barchart with 14-day historic volatility near 43% | Vendor windows differ, so risk controls should allow for wide SaaS stock movement around the August 26 earnings date. |
| Invalidation | Close below $193, then below $178 | A close below the 20-day average weakens the rebound, while a break below the 50-day area would damage the recovery setup. |
VEEV AI trading strategy
The VEEV AI trading strategy below is a rules-based research framework, not personal advice. It connects technical levels with Veeva AI adoption, Vault CRM migration, subscription revenue, operating margin, cash generation, buybacks, and competitive displacement signals.
Watch for VEEV to hold the $193 to $202 support zone and reclaim the 200-day average near $204 on stronger volume while the next earnings update confirms mid-teens revenue growth, durable subscription demand, and raised or maintained fiscal 2027 guidance.
A failed move above the 200-day average followed by a close below $193 should reduce setup confidence, especially if management commentary points to slower Vault CRM migration or weaker commercial solution demand.
If VEEV pulls back toward the $178 to $193 zone without a cut to revenue, EPS, or cash-flow guidance, compare the new price with the verified 36.1x trailing EPS, 22.5x fiscal 2027 non-GAAP EPS guidance, and 20.2x free cash flow references.
Do not treat a lower price as enough if Salesforce or IQVIA wins major accounts, AI pricing fails to convert, or pharma and biotech budgets weaken.
Track total revenue, subscription revenue, Commercial Solutions and R&D and Quality Solutions growth, Vault CRM customer migration, AI product rollout, customer count, non-GAAP operating margin, operating cash flow, share count, and cash plus short-term investments.
Position sizing should reflect that Veeva is a strong vertical software platform, but still exposed to software multiple resets and sector-specific life sciences spending cycles.
Investment research summary
Customers pay Veeva to run regulated life sciences workflows with cloud software, data, AI, and services across drug development, quality, safety, medical, commercial, and customer engagement processes.
The moat comes from industry-specific product depth, validated regulatory workflows, customer switching costs, domain trust, data models, implementation knowledge, and a customer base that includes large biopharma and emerging biotech companies.
The thesis fails if Vault CRM migration disappoints, Salesforce Life Sciences Cloud wins key accounts, AI becomes a cost of doing business rather than paid expansion, drug development budgets weaken, or the market stops paying premium multiples for vertical SaaS.
Peter Gassner founded Veeva in 2007 and remains CEO. Founder leadership is a strength, but it also creates key-person risk and raises the bar for disciplined succession, acquisition, repurchase, and product allocation decisions.
Life sciences companies need more digital compliance, faster clinical workflows, better commercial evidence, and AI-assisted productivity. The trend is favorable, but drug pricing, trial funding, and regulatory uncertainty can slow customer spending.
The current price implies that Veeva can convert its fiscal 2027 guidance, $7.31 billion cash and short-term investment base, and AI roadmap into durable per-share growth. The margin of safety is moderate, not high, because the valuation still assumes execution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $203.78 closing reference on July 31, 2026 | StockAnalysis VEEV statistics | August 2, 2026 |
| Market cap and shares outstanding | $33.10B market cap, 162.44M shares outstanding | StockAnalysis VEEV statistics | August 2, 2026 |
| Q1 fiscal 2027 revenue | $882.9M total revenue, up 16% year over year | Veeva Q1 fiscal 2027 results | August 2, 2026 |
| Q1 fiscal 2027 net income | $260.9M GAAP net income and $1.57 diluted EPS | Veeva Q1 fiscal 2027 results | August 2, 2026 |
| FY2026 revenue | $3.195B total revenue, cross-checked with Macrotrends | Veeva FY2026 results | August 2, 2026 |
| Cash and short-term investments | $7.31B as of April 30, 2026 | Veeva Q1 fiscal 2027 balance sheet | August 2, 2026 |
| Fiscal 2027 guidance | $3.635B to $3.645B revenue and about $9.05 non-GAAP diluted EPS | Veeva Q1 fiscal 2027 outlook | August 2, 2026 |
| Technical levels | RSI 62.27, 5-day MA $201.78, 20-day MA $193.73, 50-day MA $178.06, 100-day MA $173.82, 200-day MA $203.87 | Barchart VEEV technical analysis | August 2, 2026 |
| StockAnalysis technical cross-check | 50-day MA $178.06, 200-day MA $203.87, RSI 62.27, 20-day average volume 1,554,693 | StockAnalysis VEEV statistics | August 2, 2026 |
This VEEV AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, a recommendation to buy or sell securities, or a promise of future performance. Forecast ranges are scenarios based on available public data and may be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
